Semaglutide trial targets people with liver disease, obesity and alcohol addiction

Semaglutide trial targets people with liver disease, obesity and alcohol addiction

A new study -- co-led by the University of Plymouth, University Hospitals Plymouth NHS Trust, and the NIHR Biomedical Research Centre: Nottingham -- is being launched into a treatment for people impacted by liver disease, obesity and alcohol addiction.

Could weight loss drug benefit patients living with alcohol addiction, liver disease and obesity?

University of Plymouth news: Our researchers are leading a new study testing if a weight loss drug already being used to treat obesity and diabetes could also benefit patients impacted by alcoholism and obesity, two of the biggest causes of liver disease